Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

274 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A retrospective analysis of medication prescription records for determining the levels of compliance and persistence to urate-lowering therapy for the treatment of gout and hyperuricemia in The Netherlands.
Janssen CA, Oude Voshaar MAH, Vonkeman HE, Krol M, van de Laar MAFJ. Janssen CA, et al. Among authors: van de laar mafj. Clin Rheumatol. 2018 Aug;37(8):2291-2296. doi: 10.1007/s10067-018-4127-x. Epub 2018 May 2. Clin Rheumatol. 2018. PMID: 29721712 Free PMC article.
An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity: Results From a Pragmatic Open-Label Trial.
Tran-Duy A, Ghiti Moghadam M, Oude Voshaar MAH, Vonkeman HE, Boonen A, Clarke P, McColl G, Ten Klooster PM, Zijlstra TR, Lems WF, Riyazi N, Griep EN, Hazes JMW, Landewé R, Bernelot Moens HJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration. Tran-Duy A, et al. Among authors: van de laar mafj, van riel plcm. Arthritis Rheumatol. 2018 Oct;70(10):1557-1564. doi: 10.1002/art.40546. Epub 2018 Aug 23. Arthritis Rheumatol. 2018. PMID: 29745059 Clinical Trial.
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial.
Janssen CA, Oude Voshaar MAH, Vonkeman HE, Jansen TLTA, Janssen M, Kok MR, Radovits B, van Durme C, Baan H, van de Laar MAFJ. Janssen CA, et al. Among authors: van durme c, van de laar mafj. Rheumatology (Oxford). 2019 Jan 2. doi: 10.1093/rheumatology/key402. Online ahead of print. Rheumatology (Oxford). 2019. PMID: 30602035
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Van De Laar CJ, Oude Voshaar MAH, Fakhouri WKH, Zaremba-Pechmann L, De Leonardis F, De La Torre I, Van De Laar MAFJ. Van De Laar CJ, et al. Among authors: de la torre i, van de laar mafj, de leonardis f. Clinicoecon Outcomes Res. 2020 Apr 15;12:213-222. doi: 10.2147/CEOR.S231558. eCollection 2020. Clinicoecon Outcomes Res. 2020. PMID: 32346301 Free PMC article.
274 results